Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
1. FDA accepted ALDX's NDA for reproxalap review. 2. PDUFA action date set for December 16, 2025. 3. Reproxalap shows significant efficacy in treating dry eye disease symptoms. 4. Clinical trials demonstrated low safety concerns with reproxalap. 5. Aldeyra aims to engage FDA during NDA review process.